Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Non-Insulin Therapies for Diabetes market report explains the definition, types, applications, major countries, and major players of the Non-Insulin Therapies for Diabetes market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Jiangsu Hansoh Pharmaceutical
Emisphere
Eli Lilly
Dong-A Pharmaceutical
Intarcia Therapeutics
Servier
Eurofarma
GSK
SatRx
Jiangsu Hengrui Medicine
Sumitomo Dainippon Pharma
Uni-Bio Science Group
Takeda
Geropharm
Pfizer
Alkem Labs
Novo Nordisk
3SBio
Luye Pharma Group
Merck
By Type:
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
By End-User:
Hospital Pharmacy
Retail Pharmacies
Online Pharmacy
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Non-Insulin Therapies for Diabetes Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Non-Insulin Therapies for Diabetes Outlook to 2028- Original Forecasts
-
2.2 Non-Insulin Therapies for Diabetes Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Non-Insulin Therapies for Diabetes Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Non-Insulin Therapies for Diabetes Market- Recent Developments
-
6.1 Non-Insulin Therapies for Diabetes Market News and Developments
-
6.2 Non-Insulin Therapies for Diabetes Market Deals Landscape
7 Non-Insulin Therapies for Diabetes Raw Materials and Cost Structure Analysis
-
7.1 Non-Insulin Therapies for Diabetes Key Raw Materials
-
7.2 Non-Insulin Therapies for Diabetes Price Trend of Key Raw Materials
-
7.3 Non-Insulin Therapies for Diabetes Key Suppliers of Raw Materials
-
7.4 Non-Insulin Therapies for Diabetes Market Concentration Rate of Raw Materials
-
7.5 Non-Insulin Therapies for Diabetes Cost Structure Analysis
-
7.5.1 Non-Insulin Therapies for Diabetes Raw Materials Analysis
-
7.5.2 Non-Insulin Therapies for Diabetes Labor Cost Analysis
-
7.5.3 Non-Insulin Therapies for Diabetes Manufacturing Expenses Analysis
8 Global Non-Insulin Therapies for Diabetes Import and Export Analysis (Top 10 Countries)
-
8.1 Global Non-Insulin Therapies for Diabetes Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Non-Insulin Therapies for Diabetes Export by Region (Top 10 Countries) (2017-2028)
9 Global Non-Insulin Therapies for Diabetes Market Outlook by Types and Applications to 2022
-
9.1 Global Non-Insulin Therapies for Diabetes Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Alpha-glucosidase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Amylin Agonists Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Biguanides Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Dipeptidyl Peptidase-4 (DPP4) Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Glinides / Meglitinides Consumption and Growth Rate (2017-2022)
-
9.1.6 Global GLP-1 Analogs / GLP-1 Agonists Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.8 Global Sulfonylureas Consumption and Growth Rate (2017-2022)
-
9.1.9 Global Thiazolidinediones Consumption and Growth Rate (2017-2022)
-
9.1.10 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Non-Insulin Therapies for Diabetes Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Non-Insulin Therapies for Diabetes Market Analysis and Outlook till 2022
-
10.1 Global Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.2.2 Canada Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.2.3 Mexico Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.2 UK Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.3 Spain Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.4 Belgium Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.5 France Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.6 Italy Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.7 Denmark Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.8 Finland Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.9 Norway Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.10 Sweden Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.11 Poland Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.12 Russia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.3.13 Turkey Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.2 Japan Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.3 India Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.4 South Korea Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.5 Pakistan Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.6 Bangladesh Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.7 Indonesia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.8 Thailand Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.9 Singapore Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.10 Malaysia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.11 Philippines Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.4.12 Vietnam Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.2 Colombia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.3 Chile Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.4 Argentina Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.5 Venezuela Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.6 Peru Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.7 Puerto Rico Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.5.8 Ecuador Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6.2 Kuwait Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6.3 Oman Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6.4 Qatar Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6.5 Saudi Arabia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.6.6 United Arab Emirates Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.7.2 South Africa Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.7.3 Egypt Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.7.4 Algeria Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Non-Insulin Therapies for Diabetes Consumption (2017-2022)
-
10.8.2 New Zealand Non-Insulin Therapies for Diabetes Consumption (2017-2022)
11 Global Non-Insulin Therapies for Diabetes Competitive Analysis
-
11.1 Jiangsu Hansoh Pharmaceutical
-
11.1.1 Jiangsu Hansoh Pharmaceutical Company Details
-
11.1.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.1.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Emisphere
-
11.2.1 Emisphere Company Details
-
11.2.2 Emisphere Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Emisphere Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.2.4 Emisphere Non-Insulin Therapies for Diabetes Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Eli Lilly
-
11.3.1 Eli Lilly Company Details
-
11.3.2 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Eli Lilly Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.3.4 Eli Lilly Non-Insulin Therapies for Diabetes Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Dong-A Pharmaceutical
-
11.4.1 Dong-A Pharmaceutical Company Details
-
11.4.2 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.4.4 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Intarcia Therapeutics
-
11.5.1 Intarcia Therapeutics Company Details
-
11.5.2 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.5.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Servier
-
11.6.1 Servier Company Details
-
11.6.2 Servier Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Servier Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.6.4 Servier Non-Insulin Therapies for Diabetes Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Eurofarma
-
11.7.1 Eurofarma Company Details
-
11.7.2 Eurofarma Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Eurofarma Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.7.4 Eurofarma Non-Insulin Therapies for Diabetes Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 GSK
-
11.8.1 GSK Company Details
-
11.8.2 GSK Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 GSK Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.8.4 GSK Non-Insulin Therapies for Diabetes Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 SatRx
-
11.9.1 SatRx Company Details
-
11.9.2 SatRx Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 SatRx Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.9.4 SatRx Non-Insulin Therapies for Diabetes Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Jiangsu Hengrui Medicine
-
11.10.1 Jiangsu Hengrui Medicine Company Details
-
11.10.2 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.10.4 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Sumitomo Dainippon Pharma
-
11.11.1 Sumitomo Dainippon Pharma Company Details
-
11.11.2 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.11.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Uni-Bio Science Group
-
11.12.1 Uni-Bio Science Group Company Details
-
11.12.2 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.12.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Takeda
-
11.13.1 Takeda Company Details
-
11.13.2 Takeda Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Takeda Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.13.4 Takeda Non-Insulin Therapies for Diabetes Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Geropharm
-
11.14.1 Geropharm Company Details
-
11.14.2 Geropharm Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Geropharm Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.14.4 Geropharm Non-Insulin Therapies for Diabetes Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Pfizer
-
11.15.1 Pfizer Company Details
-
11.15.2 Pfizer Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Pfizer Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.15.4 Pfizer Non-Insulin Therapies for Diabetes Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Alkem Labs
-
11.16.1 Alkem Labs Company Details
-
11.16.2 Alkem Labs Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Alkem Labs Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.16.4 Alkem Labs Non-Insulin Therapies for Diabetes Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Novo Nordisk
-
11.17.1 Novo Nordisk Company Details
-
11.17.2 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Novo Nordisk Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.17.4 Novo Nordisk Non-Insulin Therapies for Diabetes Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 3SBio
-
11.18.1 3SBio Company Details
-
11.18.2 3SBio Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 3SBio Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.18.4 3SBio Non-Insulin Therapies for Diabetes Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Luye Pharma Group
-
11.19.1 Luye Pharma Group Company Details
-
11.19.2 Luye Pharma Group Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.19.4 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Merck
-
11.20.1 Merck Company Details
-
11.20.2 Merck Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Merck Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
11.20.4 Merck Non-Insulin Therapies for Diabetes Product Portfolio
-
11.20.5 Recent Research and Development Strategies
12 Global Non-Insulin Therapies for Diabetes Market Outlook by Types and Applications to 2028
-
12.1 Global Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Alpha-glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Amylin Agonists Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Dipeptidyl Peptidase-4 (DPP4) Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Glinides / Meglitinides Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global GLP-1 Analogs / GLP-1 Agonists Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.8 Global Sulfonylureas Consumption Forecast and Growth Rate (2022-2028)
-
12.1.9 Global Thiazolidinediones Consumption Forecast and Growth Rate (2022-2028)
-
12.1.10 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Non-Insulin Therapies for Diabetes Market Analysis and Outlook to 2028
-
13.1 Global Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.2.2 Canada Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.2.3 Mexico Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.2 UK Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.3 Spain Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.4 Belgium Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.5 France Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.6 Italy Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.7 Denmark Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.8 Finland Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.9 Norway Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.10 Sweden Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.11 Poland Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.12 Russia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.3.13 Turkey Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.2 Japan Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.3 India Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.4 South Korea Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.8 Thailand Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.9 Singapore Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.11 Philippines Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.2 Colombia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.3 Chile Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.4 Argentina Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.6 Peru Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6.3 Oman Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6.4 Qatar Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.7.2 South Africa Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.7.3 Egypt Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.7.4 Algeria Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Non-Insulin Therapies for Diabetes Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Non-Insulin Therapies for Diabetes
-
Figure of Non-Insulin Therapies for Diabetes Picture
-
Table Global Non-Insulin Therapies for Diabetes Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Non-Insulin Therapies for Diabetes Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Alpha-glucosidase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Amylin Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Global Dipeptidyl Peptidase-4 (DPP4) Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Glinides / Meglitinides Consumption and Growth Rate (2017-2022)
-
Figure Global GLP-1 Analogs / GLP-1 Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Sulfonylureas Consumption and Growth Rate (2017-2022)
-
Figure Global Thiazolidinediones Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Table North America Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure United States Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Canada Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Mexico Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table Europe Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure Germany Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure UK Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Spain Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Belgium Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure France Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Italy Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Denmark Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Finland Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Norway Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Sweden Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Poland Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Russia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Turkey Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table APAC Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure China Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Japan Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure India Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure South Korea Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Thailand Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Singapore Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Philippines Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table South America Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure Brazil Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Colombia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Chile Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Argentina Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Peru Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table GCC Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure Bahrain Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Oman Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Qatar Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table Africa Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure Nigeria Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure South Africa Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Egypt Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure Algeria Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table Oceania Non-Insulin Therapies for Diabetes Consumption by Country (2017-2022)
-
Figure Australia Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Non-Insulin Therapies for Diabetes Consumption and Growth Rate (2017-2022)
-
Table Jiangsu Hansoh Pharmaceutical Company Details
-
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Emisphere Company Details
-
Table Emisphere Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Emisphere Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Emisphere Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Eli Lilly Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Dong-A Pharmaceutical Company Details
-
Table Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Intarcia Therapeutics Company Details
-
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Servier Company Details
-
Table Servier Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Servier Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Servier Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Eurofarma Company Details
-
Table Eurofarma Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eurofarma Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Eurofarma Non-Insulin Therapies for Diabetes Product Portfolio
-
Table GSK Company Details
-
Table GSK Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table GSK Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table GSK Non-Insulin Therapies for Diabetes Product Portfolio
-
Table SatRx Company Details
-
Table SatRx Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table SatRx Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table SatRx Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Jiangsu Hengrui Medicine Company Details
-
Table Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Sumitomo Dainippon Pharma Company Details
-
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Uni-Bio Science Group Company Details
-
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Takeda Company Details
-
Table Takeda Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Takeda Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Geropharm Company Details
-
Table Geropharm Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Geropharm Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Geropharm Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Pfizer Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Alkem Labs Company Details
-
Table Alkem Labs Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alkem Labs Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Alkem Labs Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Novo Nordisk Non-Insulin Therapies for Diabetes Product Portfolio
-
Table 3SBio Company Details
-
Table 3SBio Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table 3SBio Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table 3SBio Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Luye Pharma Group Company Details
-
Table Luye Pharma Group Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Luye Pharma Group Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Luye Pharma Group Non-Insulin Therapies for Diabetes Product Portfolio
-
Table Merck Company Details
-
Table Merck Non-Insulin Therapies for Diabetes Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Non-Insulin Therapies for Diabetes Main Business and Markets Served
-
Table Merck Non-Insulin Therapies for Diabetes Product Portfolio
-
Figure Global Alpha-glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Amylin Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dipeptidyl Peptidase-4 (DPP4) Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Glinides / Meglitinides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global GLP-1 Analogs / GLP-1 Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Sulfonylureas Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Thiazolidinediones Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Table North America Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure United States Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure Germany Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure China Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure Brazil Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2022-2028)
-
Figure Australia Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Non-Insulin Therapies for Diabetes Consumption Forecast and Growth Rate (2022-2028)
-
